Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €2.67 EUR
Change Today +0.091 / 3.52%
Volume 14.2K
AAQ On Other Exchanges
As of 3:35 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

aap implantate (AAQ) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/3/14 - €3.65
52 Week Low
10/29/14 - €2.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AAP IMPLANTATE (AAQ)

Related News

No related news articles were found.

aap implantate (AAQ) Related Businessweek News

No Related Businessweek News Found

aap implantate (AAQ) Details

aap Implantate AG, a medical device company, researches, develops, manufactures, and sells implants, medical instruments, bone cements, and replacement materials for use in orthopedic procedures in Germany and internationally. It provides LOQTEQ, an anatomical angular stable plating system for compressing fractures with angular stable locking screws; and fragment set comprising T, L, quarter tubular, and reconstruction plates, as well as cortical and cancellous screws. It also offers cannulated screws for the treatment of hand and foot fracture; AcroPlate, which is used for the treatment of AC joint injuries; and autodynamic plating systems for secure fracture stabilization. In addition, the company provides a range of bone cements and accessories for application in arthroplasty, vertebroplasty, and kyphoplasty; and collagen fleeces for ambulant and stationary tissue care. Further, it offers bone substitutes that includes Artosal, a synthetic osteoconductive bone substitute; Cerabone, a ceramic bone substitute; OsteoCem, a calcium phosphate cement; Osnatal, a human bone allograft; and PerOssal, a synthetic bone substitute and carrier material. The company sells its products through its direct sales force, and distribution partners, as well as through license agreements with OEM partners. aap Implantate AG is headquartered in Berlin, Germany.

203 Employees
Last Reported Date: 11/14/14

aap implantate (AAQ) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €381.0K
Chief Finance Officer and Member of the Manag...
Total Annual Compensation: €260.0K
Compensation as of Fiscal Year 2013.

aap implantate (AAQ) Key Developments

AAP Stops Negotiations On The Sale Of Biomaterials

AAP Implantate AG (XTRA:AAQ) announced on March 23, 2015 that AAP Implantate stops negotiations on the sale of AAP Biomaterials Gmbh shortly before completion. AAP Implantate had reached a very advanced stage in discussions with a consortium of private equity bidders. A sale was not agreed, however, because the final transaction terms and conditions of AAP Implantate could not be met. "We were convinced until the end that we could close the transaction at attractive and mutual acceptable conditions but negotiations stalled at a critical point", says Bruke Seyoum Alemu, Chief Executive Officer of AAP Implantate.

aap Implantate AG Provides Earnings Guidance for the First Quarter and Financial Year of 2015

aap Implantate AG provided earnings guidance for the first quarter and financial year of 2015. The company aims to continue implementing its growth strategy in financial year 2015. For the full year 2015 the Management Board anticipates trauma sales growth by 20% to 25% to between EUR 14.8 million and EUR 15.4 million. In addition sales in the biomaterials business are expected to grow by 10% contributing positively to the corporate development as well. For the company as a whole the Management Board expects sales to total between EUR 33 million and EUR 35 million. The company forecasts EBITDA in the financial year 2015 of between EUR 2.5 million and EUR 3.5 million. For the first quarter of 2015 the company anticipates sales in a range of between EUR 6.5 million and EUR 7.0 million and EBITDA of between EUR -0.5 million and EUR 0.1 million. In this connection it must be mentioned that the company's economic development in the individual quarters of the financial year is expected to be in line with previous years.

AAP Implantate Seeks Acquisitions

The management of AAP Implantate AG (XTRA:AAQ) in an agenda, identified acquisitions as one of the key areas for the growth of the company.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AAQ:GR €2.67 EUR +0.091

AAQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AAQ.
View Industry Companies

Industry Analysis


Industry Average

Valuation AAQ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.1x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AAP IMPLANTATE, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at